α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage

BACKGROUND: ABT-126 is a novel, safe and well-tolerated α7 nicotinic receptor agonist in a Phase 2 Alzheimer's disease study. Here we test the antidyskinetic effect of ABT-126 in MPTP-treated squirrel monkeys with moderate and more severe nigrostriatal damage. METHODS: Monkeys (n=21, Set 1) wer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mov Disord
Main Authors: Zhang, Danhui, McGregor, Matthew, Bordia, Tanuja, Perez, Xiomara A., McIntosh, J. Michael, Decker, Michael W., Quik, Maryka
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4715565/
https://ncbi.nlm.nih.gov/pubmed/26573698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mds.26453
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados